Designing vaccines to prevent breast cancer recurrence or invasive disease

Immunotherapy

Volumn 7, Issue 2, 2015, Pages 69-72

  Stanton, Sasha E ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antigen; breast cancer prevention; MHC Class II; Th1; vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG DESIGN; HUMAN; IMMUNOGENICITY; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; REVIEW; TH1 CELL; TUMOR IMMUNITY; TUMOR INVASION; ART; BREAST NEOPLASMS; FEMALE; IMMUNOLOGY; TUMOR RECURRENCE;

BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PORTRAITS AS TOPIC;

EID: 84923880084     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.5     Document Type: Review

References (20)

1. + lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 29(15), 1949-1955 (2011).
2. + regulatory T cells. Clin. Cancer Res. 14(8), 2413-2420 (2008).
3. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a Phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol 31(7), 860-867 (2013).
4. Hussein MR, Elsers DA, Fadel SA, Omar AE. Immunohistological characterisation of tumour infiltrating lymphocytes in melanocytic skin lesions. J. Clin. Pathol. 59(3), 316-324 (2006).
5. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol 24(34), 5373-5380 (2006).
6. Muggerud AA, Hallett M, Johnsen H et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol. Oncol. 4(4), 357-368 (2010).
7. Kristensen VN, Vaske CJ, Ursini-Siegel J et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc. Natl Acad. Sci. USA 109(8), 2802-2807 (2012).
8. Kerlikowske K, Molinaro AM, Gauthier ML et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl Cancer Inst. 102(9), 627-637 (2010).
9. Nanda NK, Sercarz EE. The positively selected T cell repertoire: is it exclusively restricted to the selecting MHC? Int. Immunol. 7(3), 353-358 (1995).
10. Cecil DL, Park KH, Gad E et al. T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. Breast Cancer Res. Treat. 139(3), 657-665 (2013).
11. Park KH, Gad E, Goodell V et al. Insulin-like growth factorbinding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res. 68(20), 8400-8409 (2008).
12. Goodell V, Waisman J, Salazar LG et al. Level of HER-2/ neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol. Cancer Ther. 7(3), 449-454 (2008).
13. Czerniecki BJ, Koski GK, Koldovsky U et al. Targeting HER- 2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67(4), 1842-1852 (2007).
14. Denardo DG, Andreu P, Coussens LM. Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer Metastasis Rev. 29(2), 309-316 (2010).
15. Vanderlugt CL, Miller SD. Epitope spreading in immunemediated diseases: implications for immunotherapy. Nat Rev. Immunol. 2(2), 85-95 (2002).
16. + T cells: when, where, and how. Ann. Rev. Immunol. 24, 519-540 (2006).
17. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol. 20(1), 17-56 (2000).
18. Cecil DL, Holt GE, Park KH et al. Elimination of IL- 10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res. 74(10), 2710-2718 (2014).
19. Mokbel K, Cutuli B. Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet. Oncol. 7(9), 756-765 (2006).
20. Disis ML, Gad E, Herendeen DR et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev. Res. 6(12), 1273-1282 (2013).